Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial

被引：11

作者：

Camidge, D. Ross ^{[1
]}

Tiseo, Marcello ^{[2
]}

Ahn, Myung-Ju ^{[3
]}

Reckamp, Karen ^{[4
]}

Hansen, Karin ^{[5
]}

Kim, Sang-We ^{[6
]}

Huber, Rudolf ^{[7
]}

West, Howard ^{[8
]}

Groen, Harry ^{[9
]}

Hochmair, Maximilian ^{[10
]}

Leighl, Natasha ^{[11
]}

Gettinger, Scott ^{[12
]}

Langer, Corey ^{[13
]}

Paz-Ares, Luis ^{[14
]}

Smit, Egbert ^{[15
]}

Kim, Edward ^{[16
]}

Reichmann, William ^{[17
]}

Clackson, Tim ^{[17
]}

Kerstein, David ^{[17
]}

Haluska, Frank ^{[17
]}

Kim, Dong-Wan ^{[18
]}

机构：

[1] Univ Colorado, Ctr Canc, Aurora, CO USA

[2] Univ Hosp Parma, Med Oncol, Parma, Italy

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Meidicine, Seoul, South Korea

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Odense Univ Hosp, Odense, Denmark

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[7] Univ Hosp Munich, Munich, Germany

[8] Swedish Canc Inst, Med Oncol, Seattle, WA USA

[9] Univ Med Ctr Groningen, Groningen, Netherlands

[10] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria

[11] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[12] Yale Canc Ctr, New Haven, CT USA

[13] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[14] Hosp Univ Doce Octubre, Madrid, Spain

[15] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[16] Carolinas Healthcare Syst, Levine Canc Inst, Solid Tumor Oncol, Charlotte, NC USA

[17] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

[18] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

ALK; brigatinib; NSCLC; TKI;

D O I：

10.1016/j.jtho.2016.11.1643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02a-013

引用

页码：S1167 / S1169

页数：3

共 25 条

[1] Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK plus NSCLC
Camidge, D. R.
Ahn, M.
Reckamp, K.
West, H.
Huber, R.
Langer, C.
Bazhenova, L.
Leighl, N.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1893 - S1893
[2] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
Ahn, M.
Camidge, D. R.
Tiseo, M.
Reckamp, K.
Hansen, K.
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1755 - S1756
[3] Overall Survival (OS) After Disease Progression (PD) on Brigatinib in Patients With Crizotinib-Refractory ALK plus NSCLC in ALTA
Langer, C.
Huang, H.
Reichmann, W.
Lustgarten, S.
Kerstein, D.
Camidge, D. R.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1893 - S1894
[4] Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALKþ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Gettinger, Scott N.
Huber, Rudolf M.
Kim, Dong-Wan
Bazhenova, Lyudmila
Hansen, Karin Holmskov
Tiseo, Marcello
Langer, Corey J.
Rodriguez, Luis G. Paz-Ares
West, Howard L.
Reckamp, Karen L.
Weiss, Glen J.
Smit, Egbert F.
Hochmair, Maximilian J.
Kim, Sang-We
Ahn, Myung-Ju
Kim, Edward S.
Groen, Harry J. M.
Pye, Joanna
Liu, Yuyin
Zhang, Pingkuan
Vranceanu, Florin
Camidge, Ross
JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (09):
[5] Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Huber, Rudolf M.
Hansen, Karin H.
Paz-Ares Rodriguez, Luis
West, Howard L.
Reckamp, Karen L.
Leighl, Natasha B.
Tiseo, Marcello
Smit, Egbert F.
Kim, Dong-Wan
Gettinger, Scott N.
Hochmair, Maximilian J.
Kim, Sang-We
Langer, Corey J.
Ahn, Myung-Ju
Kim, Edward S.
Kerstein, David
Groen, Harry J. M.
Camidge, D. Ross
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) : 404 - 415
[6] Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK plus NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
Camidge, R.
Kim, H. R.
Ahn, M.
Yang, J. C.
Han, J.
Lee, J.
Hochmair, M.
Li, J. Y.
Chang, G.
Lee, K.
Gridelli, C.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D.
Bearz, A.
Griesinger, F.
Morabito, A.
Felip, E.
Califano, R.
Ghosh, S.
Spira, A.
Gettinger, S.
Tiseo, M.
Haney, J.
Kerstein, D.
Popat, S.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S185
[7] Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK plus NSCLC in the ALTA Trial
Camidge, D. R.
Tiseo, M.
Ahn, M.
Reckamp, K.
Hansen, K.
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1892 - S1892
[8] Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results
Gettinger, Scott N.
Bazhenova, Lyudmila
Salgia, Ravi
Langer, Corey J.
Gold, Kathryn A.
Rosell, Rafael
Shaw, Alice
Weiss, Glen J.
Dorer, David J.
Rivera, Victor M.
Conlan, Maureen G.
Kerstein, David
Camidge, Ross
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S238 - S239
[9] Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
Yang, James Chih-Hsin
Liu, Geoffrey
Lu, Shun
He, Jianxing
Burotto, Mauricio
Ahn, Myung-Ju
Kim, Dong-Wan
Liu, Xiaoqing
Zhao, Yanqiu
Vincent, Sylvie
Yin, Jiani
Ma, Xin
Lin, Huamao M.
Popat, Sanjay
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (12) : 1743 - 1755
[10] Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Camidge, D. Ross
Kim, Hye Ryun
Ahn, Myung-Ju
Yang, James C. H.
Han, Ji-Youn
Hochmair, Maximilian J.
Lee, Ki Hyeong
Delmonte, Angelo
Campelo, Maria Rosario Garcia
Kim, Dong-Wan
Griesinger, Frank
Felip, Enriqueta
Califano, Raffaele
Spira, Alexander I.
Gettinger, Scott N.
Tiseo, Marcello
Lin, Huamao M.
Liu, Yuyin
Vranceanu, Florin
Niu, Huifeng
Zhang, Pingkuan
Popat, Sanjay
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2091 - 2108

← 1 2 3 →